Sanofi ADR is a drug manufacturers - general business based in the US. Sanofi ADR shares (SNY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $51.50 – an increase of 1.46% over the previous week. Sanofi ADR employs 82,878 staff and has a trailing 12-month revenue of around $44.3 billion.
We currently don't have that product, but here are others to consider:
How we picked theseThe Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $51.50 |
|---|---|
| 52-week range | $45.22 - $60.12 |
| 50-day moving average | $55.32 |
| 200-day moving average | $52.79 |
| Wall St. target price | $63.84 |
| PE ratio | 21.4793 |
| Dividend yield | $3.92 (3.92%) |
| Earnings per share (TTM) | $2.42 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $49.66 from 2025-04-10
| 1 week (2025-04-04) | -4.46% |
|---|---|
| 1 month (2025-03-14) | -14.01% |
| 3 months (2025-01-14) | 2.50% |
| 6 months (2024-10-14) | -9.58% |
| 1 year (2024-04-12) | 8.12% |
|---|---|
| 2 years (2023-04-13) | -8.02% |
| 3 years (2022-04-13) | 52.4996 |
| 5 years (2020-04-13) | 30.07% |
Valuing Sanofi ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sanofi ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sanofi ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Sanofi ADR shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Sanofi ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9134. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sanofi ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Sanofi ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $11.7 billion.
The EBITDA is a measure of a Sanofi ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $44.3 billion |
|---|---|
| Operating margin TTM | 13.99% |
| Gross profit TTM | $31.1 billion |
| Return on assets TTM | 4.28% |
| Return on equity TTM | 7.3% |
| Profit margin | 12.56% |
| Book value | $61.83 |
| Market Capitalization | $132.8 billion |
TTM: trailing 12 months
Dividend payout ratio: 49.06% of net profits
Recently Sanofi ADR has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Sanofi ADR shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Sanofi ADR's case, that would currently equate to about $3.92 per share.
While Sanofi ADR's payout ratio might seem fairly standard, it's worth remembering that Sanofi ADR may be investing much of the rest of its net profits in future growth.
Sanofi ADR's most recent dividend payout was on 5 June 2024. The latest dividend was paid out to all shareholders who bought their shares by 8 May 2024 (the "ex-dividend date").
Sanofi ADR's shares were split on a 5:1 basis on 29 September 2013 . So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Sanofi ADR shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Sanofi ADR shares which in turn could have impacted Sanofi ADR's share price.
Over the last 12 months, Sanofi ADR's shares have ranged in value from as little as $45.22 up to $60.115. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sanofi ADR's is 0.482. This would suggest that Sanofi ADR's shares are less volatile than average (for this exchange).
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.